NIFTY 50 23344.75 ▲ (0.61%)
NIFTY NEXT 50 65106.15 ▲ (0.08%)
NIFTY 100 24048.8 ▲ (0.51%)
NIFTY MIDCAP 100 55106.2 ▲ (0.91%)
NIFTY SMALLCAP 100 17864.65 ▲ (1.09%)
NIFTY SMALLCAP 250 16841.4 ▲ (0.84%)
NIFTY MIDCAP SELECT 12356.5 ▲ (0.87%)
NIFTY TOTAL MARKET 12304.6 ▲ (0.6%)
NIFTY BANK 49350.8 ▲ (1.67%)
SENSEX 77073.44 ▲ (0.59%)
BSE BANKEX 56036.23 ▲ (2.03%)

JOHNSON PHARMACARE announced Financial Results for Q2 2024-25

November 17, 2024November 17, 2024| adminadmin| 0 Comments| 5:45 am
[fetch_key]
Categories:

Share the post "JOHNSON PHARMACARE announced Financial Results for Q2 2024-25"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • The presented financial data is Standalone to provide a comprehensive overview of the company performance.
  • Profit over the Year and quarter: Challenges in sustaining profitability for JOHNSON PHARMACARE LIMITED. Profit dropped by -50 % Year to Year, JOHNSON PHARMACARE LIMITED’s profitability dropped by -97.5 % Quarter to Quarter.
  • EPS over the Year and quarter:

The comprehensive analytics outlining the performance and outlook of JOHNSON PHARMACARE LIMITED‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Expenses Rs. 0 Cr Rs. 0.04 Cr Rs. 0 Cr 0 % 0 %
Operating Profit Rs. 0 Cr Rs. -0.04 Cr Rs. 0 Cr 0 % 0 %
OPM % 0 % 0 % 0 % 0 % 0 %
Other Income Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Interest Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Depreciation Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Profit before tax Rs. 0 Cr Rs. -0.04 Cr Rs. 0 Cr 0 % 0 %
Tax % -0 % -0 % -0 % 0 % 0 %
Net Profit Rs. -0 Cr Rs. -0.04 Cr Rs. -0 Cr 0 % 0 %
EPS in Rs Rs. 0 Rs. 0 Rs. 0 0 % 0 %


Today, we’re looking at JOHNSON PHARMACARE LIMITED’s financial performance for the Q2(Sep 2024-25).

In summary, JOHNSON PHARMACARE LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Expenses Rs. 0 Cr Rs. 0.04 Cr Rs. 0 Cr 0 % 0 %
Operating Profit Rs. 0 Cr Rs. -0.04 Cr Rs. 0 Cr 0 % 0 %
Net Profit Rs. -0 Cr Rs. -0.04 Cr Rs. -0 Cr 0 % 0 %
EPS in Rs Rs. 0 Rs. 0 Rs. 0 0 % 0 %


In reviewing JOHNSON PHARMACARE LIMITED’s 2024-25(Q2) financial snapshot, key trends emerge, shedding light on the company’s performance.
In essence, while JOHNSON PHARMACARE LIMITED faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”JOHNSON PHARMACARE LIMITED”]

Join our telegram for more updates

Stay Updated with Our YouTube Videos

Related Post